Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Surinder K. Batra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9470-9317; OpenAlex author ID A5085256777, A5109225893; NIH RePORTER profile ID 7239627. Sources: OpenAlex.

Their work

Papers
165 (first author 4, last author 72)
Trials
0
Grants
20
Labs led
1
Collaborators
281
Papers, trials and grants by year

2011: 11 papers, 1 grant · 2012: 10 papers, 2 grants · 2013: 11 papers, 1 grant · 2014: 5 papers · 2015: 15 papers, 2 grants · 2016: 10 papers · 2017: 4 papers · 2018: 8 papers, 3 grants · 2019: 9 papers, 1 grant · 2020: 10 papers, 1 grant · 2021: 16 papers, 1 grant · 2022: 20 papers, 2 grants · 2023: 9 papers · 2024: 7 papers, 2 grants · 2025: 8 papers, 2 grants · 2026: 12 papers, 2 grants

Papers 50 of 165

  1. A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer. Co-author DOI 10.1016/j.actbio.2026.04.026↗
  2. The underexplored complexity of pancreatic cancer: Early dissemination and quiescence. Co-author DOI 10.1016/j.bbcan.2026.189606↗
  3. NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis. Co-author DOI 10.1016/j.canlet.2026.218269↗
  4. Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218276↗
  5. Unique N-glycoproteomics and phosphoproteomics of mucins predict clinical outcomes in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218653↗
  6. SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117387↗
  7. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  8. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  9. Unveiling the gut-pancreas axis: microbial influence on stemness and tumor microenvironment of PDAC. First author DOI 10.1093/stmcls/sxaf064↗
  10. Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1096/fba.2025-00265↗
  11. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  12. Rac1 GTPase Regulates the SCFβTrCP-Mediated Degradation of Claspin and the Cellular Response of Pancreatic Cancer Cells to Gamma Rays. Co-author DOI 10.3390/cancers18121908↗
  13. Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1007/s40883-025-00394-0↗
  14. Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition. Co-author DOI 10.1016/j.isci.2025.114088↗
  15. Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41597-025-04522-x↗
  16. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  17. Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. Last author DOI 10.1080/14728222.2025.2507035↗
  18. Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis. Co-author DOI 10.3390/cancers17122031↗
  19. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.3390/cancers17162617↗
  20. Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer. Co-author DOI 10.3390/proteomes13020020↗
  21. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.217097↗
  22. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  23. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.drup.2024.101146↗
  24. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41698-024-00562-5↗
  25. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Co-author DOI 10.1053/j.gastro.2023.12.018↗
  26. PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer. Co-author DOI 10.1186/s40170-024-00354-2↗
  27. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Co-author DOI 10.3390/jcm13206211↗
  28. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216150↗
  29. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216185↗
  30. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
  31. Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression. Co-author DOI 10.1093/stmcls/sxad017↗
  32. A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-23-0825↗
  33. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12943-023-01813-y↗
  34. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Last author DOI 10.3389/fonc.2023.1073820↗
  35. Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant-Antioxidant Balance. Co-author DOI 10.3390/cancers15092593↗
  36. Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study. Co-author DOI 10.3390/jpm13050857↗
  37. Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2021.188669↗
  38. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215801↗
  39. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2022.215922↗
  40. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Last author DOI 10.1016/j.ebiom.2021.103772↗
  41. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.neo.2022.01.002↗
  42. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Co-author DOI 10.1016/j.semcancer.2022.03.021↗
  43. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Last author DOI 10.1016/j.semcancer.2022.03.022↗
  44. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Last author DOI 10.1016/j.semcancer.2022.08.009↗
  45. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Co-author DOI 10.1038/s41388-021-02047-2↗
  46. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02399-3↗
  47. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-022-02493-6↗
  48. PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Co-author DOI 10.1038/s41419-022-05258-x↗
  49. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Last author DOI 10.1053/j.gastro.2021.09.017↗
  50. A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.01.042↗

Grants 20

  1. Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer R01CA256973↗
  2. Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma U01CA200466↗
  3. Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer R01CA254036↗
  4. Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer R01CA273349↗
  5. Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer R01CA247471↗
  6. Novel Therapy to Inhibit IPMN Progression R01CA263575↗
  7. Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
  8. Targeting CXCR2 axis in Pancreatic Cancer R01CA228524↗
  9. Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia R01CA210637↗
  10. Rac1 GTPase in tumorigenesis and progression of pancreatic cancer R01CA206444↗
  11. Targeted Radiation Therapy for Pancreatic Cancer R01CA195586↗
  12. Tissue Core P50CA127297↗
  13. Targeting Mucin and EGFR Axis in Pancreatic Cancer R01CA183459↗
  14. Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer R01GM113166↗
  15. Early Diagnosis of Pancreatic Cancer U01CA111294↗
  16. Rapid Autopsy Program U54CA163120↗
  17. Targeting MUC4 for chemosensitization of pancreatic cancer R03CA167342↗
  18. Molecular Markers for the Diagnosis of Pancreatic Cancer R01CA131944↗
  19. Smoking and pancreatic cancer R01CA133774↗
  20. Molecular Studies on MUC4 Mucin Gene R01CA078590↗

Closest collaborators

The 25 strongest of 281 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moorthy Palanimuthu Ponnusamy · 54 shared papers, 2 shared grants, 2011–2026 · strength 8.73
  2. Maneesh Jain · 46 shared papers, 3 shared grants, 2011–2026 · strength 6.70
  3. Satyanarayana Rachagani · 61 shared papers, 2011–2025 · strength 5.29
  4. Sushil Kumar K · 33 shared papers, 2011–2026 · strength 3.87
  5. Jesse L. Cox · 18 shared papers, 2021–2026 · strength 3.18
  6. Sanchita Rauth · 21 shared papers, 2018–2026 · strength 3.09
  7. Kavita B. Mallya · 24 shared papers, 2011–2026 · strength 2.86
  8. Randall E. Brand · 9 shared papers, 2 shared grants, 2011–2026 · strength 2.69
  9. Michael Anthony Hollingsworth · 18 shared papers, 4 shared grants, 2011–2026 · strength 2.63
  10. Rama Krishna Nimmakayala · 18 shared papers, 2018–2024 · strength 2.62
  11. Pranita Atri · 20 shared papers, 2018–2026 · strength 2.59
  12. Parthasarathy Seshacharyulu · 25 shared papers, 2012–2026 · strength 2.59
  13. Ashu Shah · 13 shared papers, 2021–2026 · strength 2.39
  14. Michael Bouvet · 6 shared papers, 1 shared grant, 2022–2026 · strength 2.37
  15. Lynette M. Smith · 27 shared papers, 2011–2026 · strength 2.35
  16. Zahraa Wajih Alsafwani · 9 shared papers, 2023–2026 · strength 2.16
  17. Palanisamy Nallasamy · 13 shared papers, 2020–2026 · strength 2.13
  18. Michel M. Ouellette · 13 shared papers, 2 shared grants, 2013–2026 · strength 2.02
  19. Shailendra Kumar Gautam · 13 shared papers, 2017–2026 · strength 1.94
  20. Mokenge Peter Malafa · 6 shared papers, 1 shared grant, 2019–2026 · strength 1.79
  21. Namita Bhyravbhatla · 8 shared papers, 2022–2026 · strength 1.78
  22. Sukhwinder Kaur · 25 shared papers, 2011–2022 · strength 1.73
  23. Koelina Ganguly · 11 shared papers, 2019–2026 · strength 1.69
  24. Rakesh K. Singh · 6 shared papers, 2 shared grants, 2015–2026 · strength 1.66
  25. Rakesh Bhatia · 12 shared papers, 2017–2023 · strength 1.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.